Staphylococcus cohnii is a potentially biotherapeutic skin commensal alleviating skin inflammation
Yoshihiro Ito, Takashi Sasaki, Youxian Li, Takeshi Tanoue, Yuki Sugiura, Ashwin N. Skelly, Wataru Suda, Yusuke Kawashima, Nobuyuki Okahashi, Eiichiro Watanabe, Hiroto Horikawa, Aiko Shiohama, Rina Kurokawa, Eiryo Kawakami, Hachiro Iseki, Hiroshi Kawasaki, Yoichiro Iwakura, Atsushi Shiota, Liansheng Yu, Junzo Hisatsune, Haruhiko Koseki, Motoyuki Sugai, Makoto Arita, Osamu Ohara, Takeshi Matsui, Makoto Suematsu, Masahira Hattori, Koji Atarashi, Masayuki Amagai, Kenya Honda
Abstract
mice without affecting pathobiont burden. S. cohnii colonization is accompanied by activation of host glucocorticoid-related pathways and induction of anti-inflammatory genes in the skin and is therefore effective at suppressing inflammation in diverse pathobiont-independent dermatitis models, including chemically induced, type 17, and type 2 immune-driven models. As such, S. cohnii strains have great potential as effective live biotherapeutics for skin inflammation.